CanadaLocametz powder for solution, kit (Novartis Pharmaceuticals Canada Inc.), Gallium (68 Ga) Gozetotide 25 mcg/vial, DIN 02537117, Lot PG21CA2502 is affected. An unknown impurity is out of specification in the affected batch, and health care establishments should verify if their product is affected; consult your healthcare provider before discontinuing use, contact the recalling firm with questions, and report any side effects or other safety complaints to Health Canada.
What's being recalled
Depth of recall: Health Care Establishments
Companies: Novartis Pharmaceuticals Canada Inc., 100 700 Rue Saint-Hubert, Montreal QUÉBEC H2Y 0C1 CANADA.
How to identify it
Brand: Novartis Pharmaceuticals Canada Inc.; Product Name: Locametz powder for solution, kit; Market Authorization: DIN 02537117; Dosage Form: Powder For Solution, Kit; Strength: Gallium (68 Ga) Gozetotide 25 mcg/vial; Lot Number: PG21CA2502
The hazard
An unknown impurity is out of specification in the affected batch.
What to do
Verify if your product is affected.
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Contact the recalling firm if you have any questions about the recall.
Report any health product related side effects to Health Canada.
Report any other health product safety complaints to Health Canada.
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)